Therapies for heart failure: a report from the Heart Failure Congress 2007.
Rabasseda
X
X
Prous Science Medical Information Department.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002316:Cardiotonic Agents / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D015316:Genetic Therapy; D006333:Heart Failure / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D016027:Heart Transplantation; D020249:Hormone Replacement Therapy; D006801:Humans; D006835:Hydrazones / Q000627:therapeutic use; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006976:Hypertension, Pulmonary / Q000150:complications / Q000188:drug therapy; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D011724:Pyridazines / Q000627:therapeutic use; D000077464:Simendan
D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D002316:Cardiotonic Agents; D004232:Diuretics; D006835:Hydrazones; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000451:Mineralocorticoid Receptor Antagonists; D011724:Pyridazines; D000077464:Simendan